Defence Therapeutics - President & CEO, Sébastien Plouffe
President & CEO, Sébastien Plouffe
Source: LinkedIn
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Defence Therapeutics Inc. (DTC), completed good laboratory studies related to its anti-cancer AccuTOX molecule
  • AccuTOX effectively killed a large set of tumours in human and rodent samples
  • This compound also gave indication that it can be used to treat a variety of cancers
  • The studies also found that AccuTOX was well tolerated at continuous high dosages during animal testing
  • Defence Therapeutics Inc. (DTC) is up 1.50 per cent, trading at $2.03 per share as of 9:55 a.m. EST

Defence Therapeutics (DTC) has completed good laboratory studies related to its anti-cancer AccuTOX molecule and will move this work to a phase one trial.

For the past 16 months, Defence has created a library of its original Accum variants exhibiting differential effects on both immune and cancer cells.

One of the lead molecules proved to be AccuTOX, a small compound which effectively killed a large set of tumours in human and rodent samples. This compound also gave an indication that it can be used to treat a variety of cancers.

The studies also found that there were no adverse side effects for AccuTOX during rodent testing and it was well tolerated even at continuous high dosages. Defence then followed up with a second set of studies in Beagle dogs with even higher doses, where it found repetitive doses were well tolerated aside from mild skin reactions on the injected area.

Sebastien Plouffe, CEO of Defence, commented,

“The molecule is highly effective as an anti-cancer molecule and exhibits no toxic effects in different animal models… that dogs can tolerate AccuTOX up to 100 milligrams per kilogram demonstrates a larger than the expected therapeutic window for this treatment.”

The company is planning to meet with the U.S. Food and Drug Administration in the next few weeks to secure approval for launching its phase one trial against solid tumours.

The trial will test the safety and tolerability of the drug in cancer patients and assess some form of potency as a secondary objective.

Defence TheraDefence Therapeutics Inc. (DTC) is up 1.50 per cent, trading at $2.03 per share as of 9:55 a.m. EST.


More From The Market Herald

" Osisko Metals (TSXV:OM) invites investors to join them at the Vancouver Resource Investment Conference

Osisko Metals (OM) invites investors to attend the Vancouver Resource Investment Conference (VRIC).

" Plurilock (TSXV:PLUR) appoints Blake Corbet to its Board of Directors

The duo-listed cybersecurity solutions provider, Plurilock Security (PLUR), appoints Blake Corbet to its Board of Directors.

" Current Water Technologies (TSXV:WATR) signs agreement with Singapore-based Separtis Technologies Global

Current Water Technologies (WATR) has established a binding memorandum of agreement with Separtis Technologies Global Pte Ltd of Singapore.

" St Charles Resources (TSXV:SCRS.P) signs new agreement for qualifying transaction with Eastern Resources OOD

St Charles Resources (SCRS.P) has signed a business combination agreement with Eastern Resources OOD Eastern Resources.